Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Absci, AstraZeneca Enter AI-Driven Oncology Alliance | Contract Pharma

What are you searching for?

Sign in
Collaborations & Alliances

Absci, AstraZeneca Enter AI-Driven Oncology Alliance

Will leverage Absci's Drug Creation platform with the goal of accelerating the discovery of a potential new cancer treatment candidate.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Absci Corp., a generative AI antibody discovery firm, entered a collaboration with AstraZeneca to deliver an AI-designed antibody against an oncology target. The collaboration will leverage Absci’s Integrated Drug Creation platform and AstraZeneca’s expertise in oncology with the goal of accelerating the discovery of a potential new cancer treatment candidate.
 
Absci will contribute generative AI technology to deliver a therapeutic candidate antibody for a specified oncology target. The agreement includes an upfront commitment, R&D funding and milestone payments, in addition to royalties on product sales.
 
“AstraZeneca is a leader in developing novel treatments in oncology, and we are excited to collaborate with them to design a therapeutic candidate antibody with the potential to improve the lives of cancer patients,” said Sean McClain, Absci Founder & CEO. “This agreement advances Absci’s goal of creating a new generation of life-changing and transformative therapeutics using its AI platform.”
 
Puja Sapra, Ph.D., Senior Vice President of Biologics Engineering & Oncology Targeted Delivery, AstraZeneca said, “This collaboration is an exciting opportunity to utilize Absci’s de novo AI antibody creation platform to design a potential new antibody therapy in oncology.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics